ITC 2015 Header

Featured

Diet Not Linked With Thyroid Cancer

Diet Not Linked With Thyroid Cancer

New results show no significant associations between dietary habits and thyroid cancer risk.

ITC 2015 Complete Coverage

Gene Expression Classifier May Reduce Thyroid Surgery Rate

Gene Expression Classifier May Reduce Thyroid Surgery Rate

Physicians using gene expression classifier testing said that in 86% of cases, identifying a benign result through testing and potentially avoiding surgery improved patient safety.

Second Primary Malignancies Identified Among Patients With Post-Chernobyl Papillary Thyroid Cancer

Second Primary Malignancies Identified Among Patients With Post-Chernobyl Papillary Thyroid Cancer

Second primary malignancies among patients with post-Chernobyl papillary thyroid cancer include hematological malignancies, breast carcinoma, cervical carcinoma, and colon carcinomas.

Iodine Insufficiency Identified in Pediatric Patient Transitioned to Vegan Diet

Iodine Insufficiency Identified in Pediatric Patient Transitioned to Vegan Diet

Thyroid function improved after the researchers placed the child on levothyroxine and supplemented his diet with iodized salt and a multivitamin containing iodine.

Gene Variant, Fusion Panels Alone Do Not Rule In, Rule Out Thyroid Cancer

Gene Variant, Fusion Panels Alone Do Not Rule In, Rule Out Thyroid Cancer

Genetic alterations were found in both cancerous and benign samples.

Congenital Hypothyroidism May Reduce Hippocampus Activation in Verbal Memory Processing

Congenital Hypothyroidism May Reduce Hippocampus Activation in Verbal Memory Processing

Patients had reduced left middle hippocampus and right anterior hippocampus activity when judging word pairs.

VB-111 May Be Effective in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

VB-111 May Be Effective in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Use of high- and low-dose VB-111 led to 35% and 25% of patients reaching 6-month overall survival, respectively.

Aggressive Multimodal Therapy May Up Survival in Anaplastic Thyroid Cancer

Aggressive Multimodal Therapy May Up Survival in Anaplastic Thyroid Cancer

Results in this expanded series reaffirm the data in the pilot study and show a 5-year overall survival rate of 43%.

Cabozantinib Improved Survival in Medullary Thyroid Cancer With RET Mutations

Cabozantinib Improved Survival in Medullary Thyroid Cancer With RET Mutations

Patients with medullary thyroid cancer taking cabonzantinib lived more than 2 years longer if their tumors had a RET mutation.

Upcoming Meetings

Sign Up for Free e-Newsletters